STRO
SUTRO BIOPHARMA, INC.
NASDAQ · Healthcare · Biotechnology · US
$11.26
+2.88%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$11.01
From 52W high−72.49%
Volume299593.00
Market cap$186.62M
P/E (TTM)—
P/S (TTM)4.1x
Div yield—
Key dataOct 19, 2026
Open
$11.01
From 52W high
−72.49%
Volume
299593.00
Market cap
$186.62M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
P/E (TTM)
—
RSI (14)
28.3
MomentumView details →
1D Return
+2.88%
YTD Return
−1.90%
SummaryUpdated Jun 1, 2026
Sutro Biopharma, Inc. (NASDAQ:STRO) is a clinical-stage biotechnology company founded in 2003 and headquartered in South San Francisco, California. Originally incorporated as Fundamental Applied Biology, Inc., the company went public in September 2018. Sutro specializes in developing protein therapeutics for cancer and autoimmune disorders using its proprietary cell-free protein synthesis platform called XpressCF+. The company focuses on creating antibody-drug conjugates (ADCs) and other targeted therapies, with multiple drug candidates currently in clinical trials.
Similar companies
Latest newsMore news →